Rationale: Intravascular neutrophil recruitment and activation are key pathogenic factors that contribute to vascular injury. Intravenous immunoglobulin (IVIG) has been shown to have a beneficial effect in systemic inflammatory disorders; however, the mechanisms underlying IVIG's inhibitory effect on neutrophil recruitment and activation are not understood.
A ccumulation and recruitment of polymorphonuclear neutrophils are key pathogenic factors in the development of microvascular obstruction in cardiovascular disease, including sickle cell disease (SCD). 1, 2 Neutrophils are the major leukocyte subset recruited to inflamed venules, and the adherence of activated neutrophils to endothelial cells is a critical step that leads to reduction of the microcirculatory blood flow, ischemia, hypoxia, and tissue damage. [3] [4] [5] [6] Therefore, pharmacological approaches to inhibit neutrophil recruitment and activation represent important strategies to prevent vascular injury.
Intravenous immunoglobulin (IVIG) is a unique immunemodulating therapy that has a variety of effects on the immune system, depending on the underlying pathogenesis of given disease. 7 The protective actions of IVIG in autoimmune diseases have been characterized, including modulation of immunoglobulin (Ig)G Fc receptor expression, alteration of cytokine levels, complement inhibition, and modification of B-cell and T-cell functions. 7, 8 However, the molecular mechanisms by which IVIG exerts inhibition of neutrophil recruitment and activation in systemic acute inflammation remain to be understood. Direct observation of leukocyte recruitment by intravital microscopy has revealed that IVIG inhibits selectin-mediated leukocyte rolling and ␤2 integrin-dependent leukocyte adhesion to endothelium. 9 -12 In SCD mice, IVIG reverses acute vaso-occlusive crisis (VOC) by inhibit-ing neutrophil adhesion to the endothelium and abrogating the direct interactions between adherent leukocytes and circulating red blood cells (RBCs). 9, 11 Fc␥ receptors (Fc␥Rs) for IgG are expressed on a wide variety of hematopoietic cells, linking cellular and humoral immunity. The family of Fc␥Rs has been categorized into 2 different classes: the activating (Fc␥RI, Fc␥RIII, and Fc␥RIV) and inhibitory (Fc␥RIIB) receptors. Engagement of activating Fc␥Rs associated with the common ␥-chain triggers effector cell responses, such as antibody-dependent cell-mediated cytotoxicity, phagocytosis, reactive oxygen production, and release of inflammatory mediators, whereas the inhibitory Fc␥RIIB mediates the inhibition of activating Fc␥R-induced signal cascade. 13 During inflammation, Fc␥Rs play important roles in leukocyte recruitment and activation. Fc␥RIII mediates neutrophil tethering and adhesion in response to immune complexes in autoimmune disease. 14, 15 ␤2 integrins, particularly Mac-1, cooperate with Fc␥Rs to sustain neutrophil adhesion. 16 In addition, the common ␥-chain containing immunoreceptor tyrosine-based activation motifs (ITAMs) is involved in the initial signaling events that are required to initiate E-selectin-mediated neutrophil slow rolling and outside-in signaling through ␤2-integrins in neutrophils. 17, 18 However, the mechanisms by which IVIG engagement to Fc␥Rs modulates intravascular neutrophil recruitment and activation in the context of inflammation are incompletely defined.
We elucidate the mechanism by which IVIG exerts inhibition of intravascular accumulation and activation of neutrophils to localized inflamed area in vivo using real-time intravital microscopy. We show that engagement of IVIG to activating Fc␥RIII but not the inhibitory Fc␥RIIB inhibits leukocyte recruitment, abrogates heterotypic adherent leukocyte-RBC interactions, and reduces Mac-1 activity. In addition, we identify the protein tyrosine phosphatase SHP-1 as a critical downstream mediator involved in the Fc␥RIIImediated inhibitory effects of IVIG on leukocyte recruitment and activation.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Mice
Berkeley SCD mice [Tg(Hu-miniLCR␣1 G ␥ A ␥␦␤ S ) Hba Ϫ/Ϫ Hbb Ϫ/Ϫ ] have been previously described. 19 Fcgr2b Ϫ/Ϫ 20 and Fcgr3 Ϫ/Ϫ 21 mice, generated by gene targeting, were purchased from The Jackson Laboratory (Bar Harbor, ME). Homozygous mice for the motheaten viable (me ) mutation were established by mating C57BL/6J-Ptpn6 me-v /J (ϩ/me v ) heterozygous breeding pairs obtained from The Jackson Laboratory. Additional details of fully chimeric SCD and me /me mice refer to the online supplemental materials. All experimental procedures performed on mice were approved by the Animal Care and Use Committee of Mount Sinai School of Medicine and Albert Einstein College of Medicine.
Intravital Microscopy and Image Analyses
The cremasteric muscle was prepared as described in the Online Data Supplement Methods. Either IVIG (800 mg/kg) or an equivalent volume of control human albumin was intravenously infused by programmable syringe pump (PHD 4400, Harvard Apparatus, Holliston, MA) at the rate of 667 L/kg per minute 3 hours after intrascrotal injection of 0.5 g tumor necrosis factor (TNF)-␣. Then, 20 minutes after IVIG or control albumin exposure, 8 to 12 venules were videotaped over a period of 60 minutes, with each venule recorded continuously for at least 2 minutes. To block endogenous Fc␥RIIB/III, we injected 1 mg/kg i.v. anti-Fc␥RIIB/III or control isotype rat IgG2b, before administration of either IVIG or control albumin. Bright-field intravital microscopy was performed, using video recordings, and all data were analyzed by playback assessment of video-captures as described in the Online Data Supplement Methods.
Hemodynamic Measurements
Arteriolar and venular diameter was measured with a video caliper before and after administration of either IVIG or control albumin. Centerline red cell velocities (V RBC ) were determined for each venule in real-time, using an optical Doppler velocimeter (Texas A&M, College Station, TX). Wall shear rate and blood flow rate were calculated as described in the Online Data Supplement Methods.
In Vivo Analysis of Mac-1 Activity
Albumin-coated fluospheres were intravenously injected into mice prepared for intravital microscopy as described in detail in the Online Data Supplement Methods. Images were captured for at least 30 seconds in the bright-field and FITC (for yellow-green fluospheres) channels and analyzed them with SlideBook software (Intelligent Imaging Innovations). Adherent leukocytes were visually identified in the bright-field channel and the number of fluospheres associated to each leukocyte was counted. The average number of albumincoated fluospheres bound to adherent intravascular leukocytes in a given 100-m-long venular segment was used as a measure of Mac-1 activity and was obtained from the formula: fluospheres/white blood cells (WBC)ϭtotal number of leukocyte-associated beads per venular segment/number of adherent leukocytes per venular segment, as previously described. 22
Flow Cytometry Analyses
Blood samples were collected into sterile tubes containing 2 mmol/L ethylenediaminetetraacetic acid (EDTA) and lysed in 0.8% NH 4 Cl lysis buffer and the remaining nucleated cells were washed twice in PBS containing 2 mmol/L EDTA and 0.5% BSA (PEB buffer). Primary blood leukocytes were stained by incubation with fluorescently labeled or biotinylated antibodies specific to mouse or corresponding with isotype controls. Biotinylated monoclonal antibody (mAb) was detected by incubation with Cy5-conjugated streptavidin (Jackson ImmunoResearch Laboratories). Stained samples were acquired with a FACSCalibur flow cytometer (Becton Dickinson, Mountain View, CA) and an LSRII (BD) and then analyzed with FlowJo software (Tree Star, Inc). Leukocytes and neutrophils were gated on the basis of low forward-scatter and high side-scatter characteristics. 
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Immunoprecipitation and Western Blotting
Proteins were extracted from bone marrow neutrophils isolated from WT and Fcgr2b Ϫ/Ϫ mice, and the association of SHP-1 with Fc␥RIIB/III was analyzed by immunoprecipitation and Western blotting as described in the Online Data Supplement Methods.
Statistical Analyses
All data are presented as meanϮSEM and analyzed using unpaired, 2-tailed Student t test or nonparametric Mann-Whitney U test, as appropriate. A probability value of Ͻ0.05 was considered statistically significant.
Results
Low-Affinity Fc␥ Receptors Alter Intravascular Cell Interactions in Wild-Type Animals
Low-affinity activating Fc␥RIII and its inhibitory counterpart, Fc␥RIIB, have been suggested to be involved in IVIGmediated immunomodulation in diverse murine models of autoantibody-triggered immune diseases. [23] [24] [25] We thus investigated whether Fc␥RIIB/III were required for IVIG's suppressive effects on leukocyte recruitment in systemic acute inflammation in wild-type (WT) mice. To test this, either mAb against Fc␥RIIB/III or control isotype rat IgG2b was injected to block endogenous Fc␥RIIB/III before administration of IVIG or control human albumin into WT C57BL/6 mice treated systemically with TNF-␣ ( Figure 1A ). Injection of Fc␥RIIB/III mAb was sufficient to saturate endogenous Fc␥RIIB/III antigens on neutrophils by Ͼ98%, compared with control IgG2b injection ( Figure 1B ). We then evaluated the effects of IVIG on leukocyte recruitment by direct observation using intravital microscopy in the microvasculature of the WT mice. We infused human albumin to control for potential changes in intravascular oncotic pressures from high-dose IVIG. 9,11 IVIG administration did not alter the number of circulating leukocytes and the percentage of major leukocyte subsets, including lymphocytes, neutrophils, and monocytes, compared with control albumin administration in the presence and absence of endogenous Fc␥RIIB/III expression on leukocytes ( Figure 1 , C and D). In addition, IVIG administration did not cause vasodilation or alter hemodynamic parameters (ie, blood flow, centerline velocity and shear rate) compared with the albumin-infused control group in WT mice (Online Figure I, A and B, and Online Table I ).
Interestingly, IVIG administration significantly inhibited leukocyte adhesion to endothelium (Ϸ30% reduction, 875Ϯ54 versus 1298Ϯ68 adherent WBCs/mm 2 ; PϽ0.001), whereas Fc␥RIIB/III blockade negated its inhibitory effect on leukocyte adhesion to endothelium (1221Ϯ95 versus 1232Ϯ68 adherent WBCs/mm 2 ) compared with control albumin administration in microvessels with identical average venular diameter ( Figure 1C and Online Table I ).
The microvascular obstruction is a complex multicellular process involving endothelial activation, leukocyte adhesion to endothelium, and the direct interaction of circulating RBCs and adherent leukocytes (WBCs). 26 In previous studies, we demonstrated that interactions between adherent leukocytes and RBCs carrying normal hemoglobin (nRBC) occurred in inflamed venules under relatively low shear rates (Ͻ500 s Ϫ1 ). 22 We thus examined whether IVIG infusion could inhibit the interactions between adherent leukocytes and nRBCs. IVIG administration significantly reduced heterotypic interactions between adherent leukocytes and circulating nRBC interactions (67% reduction, 0.05Ϯ0.01 versus 0.15Ϯ0.02 RBC-WBC interactions/min; PϽ0.001), whereas Fc␥RIIB/III blockade abrogated its inhibitory action on heterotypic interactions (0.16Ϯ0.02 versus 0.15Ϯ0.02 RBC-WBC interactions/min) under similar hemodynamic conditions ( Figure 1D and Online Table II ). These results demonstrate a clear requirement for Fc␥RIIB/III for the protective actions of IVIG on leukocyte recruitment and activation during acute inflammation, suggesting that IVIG might modulate their expression or function.
Fc␥RIII But Not Fc␥RIIB Is a Major Fc␥ Receptor on Neutrophils
In previous studies, we found that IVIG specifically targets the recruitment of neutrophils, which make up the majority of adherent leukocytes in inflamed venules. 3, 9 We therefore examined the cell surface expression of both Fc␥RIIB and Fc␥RIII on circulating neutrophils using myeloid lineagespecific markers (ie, Gr-1, CD115, and F4/80). Gr-1 hi and CD115 low neutrophils were labeled by a dual-specific antibody to Fc␥RIIB/III, but barely by one directed at Fc␥RIIB, compared with expression levels of positive CD115 hi monocyte and negative CD3 pos T-cell controls (Figure 2A ). Because the high degree of homology between Fc␥RIIB and Fc␥RIII has prevented the generation of specific antibodies against individual low-affinity Fc␥ receptors, we used Fc␥RIII-deficient (Fcgr3 Ϫ/Ϫ ) mice to examine further the surface expression of Fc␥RIIB on neutrophils. In Gr-1 hi CD115 low neutrophils, the binding of the antibody recognizing Fc␥RIIB/III in Fcgr3 Ϫ/Ϫ mice was virtually undetectable, compared with WT mice ( Figure 2B and Online Figure II ), suggesting that mouse neutrophils constitutively express Fc␥RIII but little or no Fc␥RIIB in the steady state.
It has been proposed that the benefits of IVIG may result from the induction of expression of inhibitory Fc␥RIIB on tissue-infiltrating macrophages, thereby raising the threshold required for triggering activating Fc␥Rs in autoimmune disease. 23, 27 Thus, we sought to determine whether low affinity Fc␥RIIB/III expression on neutrophils is changed after IVIG administration. We found that the expression levels of Fc␥RIIB/III on neutrophils did not change 1 hour after administration of IVIG or control albumin into control WT, Fc␥RIIB-deficient (Fcgr2b Ϫ/Ϫ ), and Fcgr3 Ϫ/Ϫ mice ( Figure 2C ). These results indicate that IVIG administration does not induce inhibitory Fc␥RIIB expression on neutrophils and that the activating Fc␥RIII is a major receptor in murine neutrophils.
IVIG Inhibition of Leukocyte Recruitment and Activation Is Mediated by Fc␥RIII
In mice, both inhibitory Fc␥RIIB and activating Fc␥RIII are important for IVIG-mediated amelioration of inflammation. [23] [24] [25] 27 To determine the differential contribution of Fc␥RIIB and Fc␥RIII to IVIG-mediated protection, we assessed leukocyte recruitment and heterotypic interactions between adherent leukocytes and circulating RBCs after IVIG or control albumin administration in the context of systemic acute inflammation in control WT, Fcgr2b Ϫ/Ϫ , or Fcgr3 Ϫ/Ϫ mice. As compared with control albumin, IVIG administration significantly reduced leukocyte adhesion to endothelium by approximately 30% to 40% in both control WT (1108Ϯ88 versus 1439Ϯ117 adherent WBCs/mm 2 , PϽ0.05) and Fcgr2b Ϫ/Ϫ mice (890Ϯ84 versus 1523Ϯ112 adherent WBCs/mm 2 , PϽ0.01). Strikingly, its inhibitory effect on leukocyte recruitment was absent in Fcgr3 Ϫ/Ϫ mice (1201Ϯ87 versus 1145Ϯ51 adherent WBCs/mm 2 ; Figure 3A and Online Table III ). Furthermore, IVIG administration significantly reduced RBC interactions with adherent leukocytes by 50% under relatively low shear rates (Ͻ500 s Ϫ1 ) in both control WT (0.12Ϯ0.02 versus 0.23Ϯ0.03, RBC-WBC interactions/min; PϽ0.01) and Fcgr2b Ϫ/Ϫ (0.10Ϯ0.02 versus 0.19Ϯ0.03 RBC-WBC interactions/min; PϽ0.05) mice but not Fcgr3 Ϫ/Ϫ (0.30Ϯ0.04 versus 0.26Ϯ0.05, RBC-WBC interactions/min) mice compared with control albumin administration ( Figure 3B and Online Table IV) .
Activated Mac-1 integrin microdomains at the leading edge of neutrophils, a phenomenon that is triggered by E-selectin expressed on the inflamed endothelium, drive vascular damage in SCD through heterotypic interactions. 22 We thus assessed the effect of IVIG on Mac-1 activity in adherent leukocytes using a previously validated in vivo fluosphere bead-binding assay. 22 This specifically assay measure Mac-1 activity on adherent neutrophils, since albumincoated fluospheres captured by adherent Gr-1 pos F4/80 neg neutrophils have been shown to be absent in Mac-1-deficient (Itgam Ϫ/Ϫ ) mice. 22 Overlay of images acquired in bright-field and fluorescence channels revealed that the capture of albumin-coated fluorescent beads by adherent leukocytes was strongly inhibited in IVIG-infused mice ( Figure 3C ). In parallel with the reduction in heterotypic interactions with RBCs seen after IVIG treatment, IVIG administration significantly reduced Mac-1 activity in leukocytes compared with control albumin administration in both control WT and Fcgr2b Ϫ/Ϫ mice. However, IVIG-induced reduction of Mac-1 activity was abrogated in Fcgr3 Ϫ/Ϫ mice ( Figure 3D ). Taken together, these results indicate that Fc␥RIII mediates IVIGinduced inhibition of leukocyte adhesion to endothelium, heterotypic RBC interactions with adherent leukocytes, and Mac-1 integrin activation.
Involvement of SHP-1 in the Inhibitory Effect of IVIG on Leukocyte Recruitment
Previous studies have provided evidence that activating Fc␥Rs associated with ITAMs can induce inhibitory signaling mediated by recruitment of Src homology 2(SH2)containing tyrosine phosphatase-1 (SHP-1). 28, 29 The tyrosine phosphatase SHP-1 can act as a negative regulator that dephosphorylates multiple immunoreceptor-regulated substrates, leading to cell inactivation. 30 We hypothesized that IVIG induces the recruitment of SHP-1 to Fc␥RIII in neutrophils, thereby inactivating ITAM-induced activating signal cascade through dephosphorylation. To assess whether SHP-1 is recruited to Fc␥RIII in response to IVIG, bone marrow neutrophils isolated from control WT mice were incubated with either IVIG or control albumin and then analyzed the association of SHP-1 with Fc␥RIIB/III. As compared with either resting or albumin-treated bone marrow neutrophils, IVIG treatment induced the recruitment of SHP-1 to Fc␥RIIB/III in neutrophils from WT mice ( Figure  4A ). In addition, IVIG-induced SHP-1 recruitment to Fc␥RIIB/III was also observed in neutrophils from Fcgr2 Ϫ/Ϫ mice (Online Figure III) . This indicates SHP-1 associates with Fc␥RIII in response to IVIG, suggesting that SHP-1 may be involved in Fc␥RIII-mediated inhibitory pathways induced by IVIG.
We next gauged the role of SHP-1 in IVIG's antiinflammatory effect on leukocyte recruitment and activation by assessing motheaten viable (me /me ) mice that have reduced phosphatase activity due to a mutation inSHPTP1. 31 Neutrophils from me /me mice show increased oxidative production, surface expression of ␤2 integrins, and leukocyte adhesion in vitro, 32 suggesting a significant role for SHP-1 in modulating the tyrosine phosphorylation signaling pathways that regulate neutrophil activation. To analyze the contribution of SHP-1 in the hematopoietic lineage, we generated chimeras by transplantation of WT and me /me bone marrow donors into WT recipients (Online Figure IV, A and B) . In contrast to WT chimeras, administration of IVIG in me /me bone marrow chimeras did not alter leukocyte recruitment, RBC interactions with adherent leukocytes, and Mac-1 activity ( Figure 4B through 4D and Online Table V and VI) . Taken together, these results suggest that IVIG mediates its inhibitory effect on leukocyte recruitment and activation via recruitment of SHP-1 to Fc␥RIII.
Fc␥RIII Mediates the Protective Effect of IVIG Against Acute VOC
Acute VOC is the most common complication of SCD and is a major cause of morbidity and mortality for SCD patients. 33 Previous studies have established that IVIG can reverse acute VOC in a humanized murine model of SCD via specific inhibition of neutrophil recruitment and their interactions with circulating RBCs. 9, 11 We thus tested whether engagement of the low-affinity receptors Fc␥RIIB/III mediate the protective effect of IVIG on acute VOC in SCD similar to systemic acute inflammation in WT mice. We injected mice with a mAb against Fc␥RIIB/III or control isotype rat IgG2b, before IVIG or control human albumin administration in TNF-␣-treated SCD mice ( Figure 5A ). Injection of 1 mg/kg Fc␥RIIB/III mAb was sufficient to saturate endogenous Fc␥RIIB/III antigens on neutrophils by Ͼ96%, compared with control IgG2b injection ( Figure 5B ). Consistent with previous studies, 9, 11 IVIG administration significantly reduced leukocyte adhesion to endothelium (Ϸ30% reduction, 1303Ϯ96 versus 1961Ϯ123 adherent WBCs/mm 2 ; PϽ0.01) and heterotypic adherent leukocyte-RBC interactions (Ͼ98% reduction, 0.01Ϯ0.001 versus 0.80Ϯ0.3 RBC-WBC interactions/min; PϽ0.001) in control IgG2b-treated SCD mice ( Figure 5C and D) . Although IVIG administration did not cause vasodilatory response in both arteries and veins, its infusion significantly improved blood flow rates, a surrogate measure for vaso-occlusion, compared with the albumininfused control group (PϽ0.01, Figure 5E and Online Figure  V, A and B) , as well as the mean centerline RBC velocity (V RBC ) and wall shear rate in venules (PϽ0.01, respectively; Table) . Importantly, blockade of endogenous Fc␥RIIB/III abrogated IVIG's alteration of leukocyte adhesion to endothelium (2100Ϯ134 versus 2026Ϯ181 adherent WBCs/mm 2 ), heterotypic adherent leukocyte-RBC interactions (0.26Ϯ0.06 versus 0.28Ϯ0.10 RBC-WBC interactions/min), and blood flow rates (271Ϯ16 versus 265Ϯ15 nL/s) ( Figure 5C through  5E ). Furthermore, IVIG-induced inhibitory effect on leuko- Bone marrow neutrophils isolated from control WT mice (nϭ3) were incubated with IVIG or albumin (6.7 mg/mL) at 37°C for 15 minutes, and then lysates were prepared. Lysates were immunoprecipitated (IP) with anti-Fc␥RIIB/III or control isotype rat IgG2b followed by immunoblotting (IB) with anti-SHP-1/2 ab. B, Adherent leukocytes in venules. C, Number of circulating RBC-adherent leukocyte interactions per minute. Bars represent meanϮSEM. *PϽ0.05, ***PϽ0.001 versus albumin. D, Binding of albumin-coated flurospheres to leukocytes10 minutes after either IVIG or control albumin administration in control chimeric WT or me / me mice. Each dot represents the average number of fluospheres bound per leukocyte within individual venules (nϭ20 -28 venules from 4 mice per group). ***PϽ0.001 versus albumin, Mann-Whitney test.
cyte recruitment led to reduced sickling, resulting in protection from intermittent vaso-occlusion in postcapillary venules, whereas Fc␥RIIB/III blockade abrogated IVIG's suppressive effect on acute vaso-occlusion ( Figure 5F and Online Movies I to IV). In addition, IVIG significantly prolonged the survival time of SCD mice compared with the albumin-infused control group (PϽ0.05, log-rank test), whereas Fc␥RIIB/III blockade abrogated the survival benefit ( Figure 5G ). Taken together, endogenous Fc␥RIIB/III blockade negated the protective effect of IVIG on acute VOC in SCD mice, thus demonstrating that the beneficial effects of IVIG during neutrophil-mediated acute injury result from the interaction with, and signaling through, Fc␥RIII.
Discussion
IVIG is an effective therapeutic agent in a variety of autoimmune diseases or chronic inflammatory disorders. The mech-anisms of IVIG action have been most thoroughly investigated in autoantibody-mediated diseases, but the exact mechanism by which IVIG prevents leukocyte recruitment and activation during acute vascular injury remains poorly understood. Using intravital microscopy, we have directly studied the roles of IVIG in intravascular neutrophil recruitment and activation in TNF-␣-induced acute inflammation. Our data demonstrate that IVIG inhibits leukocyte adhesion to endothelium and heterotypic RBC interactions with adherent leukocytes by reducing Mac-1 activity on neutrophils. In addition, our studies identify Fc␥RIII as the Fc␥R required for mediating IVIG's anti-inflammatory activity. Engagement of IVIG to Fc␥RIII induces recruitment of the protein tyrosine phosphatase, SHP-1, which subsequently inhibits leukocyte recruitment and activation (Online Figure VI) .
The anti-inflammatory activity of high-dose IVIG can be attributed to the minor fraction of dimeric or sialylated IgG in Pϭ0.03, log-rank test, IVIG versus albumin in IgG2b-treated group; Pϭ0.93, log-rank test, IVIG versus albumin in anti-Fc␥RIIB/III mAbtreated group. a murine model of immune thrombocytopenic purpura that macrophages are responsible for the clearance of autoantibody-coated platelets. 23, 34, 35 These studies have suggested that IVIG increases expression of the inhibitory receptor Fc␥RIIB on the surface of inflammatory macrophages, thereby resulting in suppression of autoantibodytriggered inflammation. 23, 36 Thus, macrophages containing Fc␥RIIB in autoantibody-mediated disorders are the effector cells in the anti-inflammatory response mediated by IVIG. Because neutrophils represent the vast majority of adherent leukocytes in inflamed venules and are specifically targeted by IVIG in SCD, 9 we have examined the surface expression of Fc␥RIIB and Fc␥RIII on IVIG-treated neutrophils. Our results show that neutrophils predominantly express Fc␥RIII but not Fc␥RIIB in the steady state. Interestingly, IVIG administration did not alter the surface expression of either inhibitory Fc␥RIIB or activating Fc␥RIII on neutrophils. Based on our data and previous studies, IVIG may therefore differentially act on distinct effector cells or potentially affect various leukocyte subsets through different mechanisms of action.
Neutrophil recruitment during inflammation is classically attributed to a multistep cascade involving selectin-mediated initial tethering and rolling along the vessel wall, followed by ␤2 integrin-mediated firm adhesion to the vascular endothelium. 37 During leukocyte recruitment, IVIG modulates these adhesion molecules, including PSGL-1, Mac-1(␣M␤2), and LFA-1(␣L␤2) on leukocytes. 10, 38 Moreover, analyses of leukocyte recruitment by intravital microscopy have also revealed that IVIG can inhibit P-selectin-dependent leukocyte rolling, E-selectin-mediated slow rolling, and ␤2 integrindependent leukocyte adhesion to the endothelium in vivo suggesting that IVIG directly targets leukocytes. 9 -11 The receptors and signaling pathways potentially involved in this direct inhibitory effect remain poorly understood. We found that blockade of endogenous Fc␥RIIB/III abrogated IVIG's anti-inflammatory activity during leukocyte recruitment. In addition, the inhibitory effects of IVIG on leukocyte recruitment and activation were abolished in Fcgr3 Ϫ/Ϫ mice, indicating the requirement of Fc␥RIII to mediate IVIG's antiinflammatory activity during leukocyte recruitment.
Activating Fc␥RIII is associated with the common ␥-chain, which contains an ITAM motif. Although ITAMs are used by multiple receptors to activate immune cells, recent studies have suggested that ITAMs can paradoxically function to propagate inhibitory signals under specific conditions. 39 ITAM-mediated inhibition downstream of activating Fc␥Rs can occur when a low-affinity ligand favors the recruitment of a signaling effector such as protein tyrosine phosphatase SHP-1 with inhibitory potential instead of activation of signal-promoting kinases. 28, 29 In agreement with this contention, our data show that the protein tyrosine phosphatase SHP-1 is recruited to Fc␥RIII in IVIG-treated neutrophils compared with either resting or albumin-treated neutrophils, suggesting that IVIG induces recruitment of SHP-1 to Fc␥RIII in neutrophils.
IVIG significantly increases leukocyte rolling velocities, suggesting that it alters adhesion pathways involving E-selectin. 9 Interestingly, E-selectin engagement cannot induce LFA-1-dependent slow rolling in the absence of ITAMassociated with immunoreceptor in leukocytes. 40 E-selectinmediated intracellular signaling pathways in neutrophils indeed exhibit strong similarities to that of Fc␥R or ␤2 integrin-mediated outside-in signaling. Binding of neutrophils to E-selectin on inflamed endothelium activates Src family kinases, which in turn activates ITAM-dependent pathways, such as spleen tyrosine kinase, phosphoinositide-3-kinase, and p38 mitogen-activated protein kinase, resulting in LFA-1-dependent slow rolling and Mac-1 activation at the leading edge of adherent neutrophils. 18,22,40 -42 Since protein tyrosine phosphatases such as SHP-1 can switch off ITAMinduced activating signaling cascades, 30 our results suggest the possibility that the recruitment of SHP-1 in response to IVIG inactivates ITAM-mediated signals, including E-selectin-induced and Fc␥RIII-induced pathways. This results in alteration in neutrophil responses triggered by these receptors: Mac-1 activation, reduced ␤2 integrin-dependent neutrophil arrest, and reduced Mac-1-dependent RBC interactions. Therefore, signaling pathways controlled by SHP-1 phosphatase may become therapeutic targets to control neutrophil functions in inflammatory disease.
Of particular relevance, we assessed the contribution of Fc␥Rs in IVIG-induced protection from VOC in the context of SCD. Consistent with the central role of integrin activation and RBC capture by neutrophils during vascular occlusion, blockade of Fc␥RIIB/III before IVIG delivery prevented all the beneficial effects associated with this treatment. In addition, IVIG inhibits ROS-producing neutrophils in a experimental model of transfusion-related acute lung injury, in which mechanisms similar to those leading to vaso-occlusion promote vascular and organ injury (data not shown). 22 These results suggest that other types of vascular disease could also be benefit from the insights on IVIG's mode of action reported herein. For example, neutrophils have been recently shown to participate in chronic arterial disease, including atherosclerosis 43 or restenosis. 44 One could envision that prolonged neutrophil activation, through mechanisms partly shared with the acute processes described here, contributes to vascular injury in large vessels. Hemodynamic parameters were analyzed from intravital microscopy recording of venules used for the results shown in Figure 5C and 5D. Data are presented as meanϮSEM.
Table. Hemodynamic Parameters After IVIG or Control Albumin Administration Following Injection of Anti-Fc␥RIIB/III mAb or IgG2b Control in TNF-␣-Treated SCD Mice
*PϽ0.01 versus albumin.
In summary, this study reveals an inhibitory role for Fc␥RIII in response to IVIG, resulting in recruitment of SHP-1 and preventing neutrophil adhesion and activation in areas of vascular injury. Therefore, elucidating the target signals affected by IVIG-induced SHP-1 recruitment will provide novel insights for designing therapeutic strategies that prevent vascular disease.
